Full-Time
Clinical-stage pharma developing rare endocrine therapies
$178k - $223k/yr
San Diego, CA, USA
In Person
Crinetics Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for rare endocrine diseases and endocrine-related tumors. Its work centers on creating novel orally administered treatments, with CRN00808 for acromegaly currently in Phase 2 trials. The product approach involves identifying targets in endocrine pathways (often GPCRs), and engineering oral drug candidates that modulate these targets to treat conditions with few existing options. The company differentiates itself by concentrating on rare endocrine disorders and advancing candidates through clinical development, aiming to secure regulatory approvals and then pursue commercialization, often via partnerships or licensing with larger pharma players. Its goal is to provide effective, targeted therapies for patients with unmet endocrine needs and to bring approved medicines to market through disciplined clinical development and external collaborations.
Company Size
501-1,000
Company Stage
IPO
Headquarters
San Diego, California
Founded
2008
Help us improve and share your feedback! Did you find this helpful?
People at Crinetics Pharmaceuticals who can refer or advise you
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Holidays
Unlimited Paid Time Off
PTO/vacation
Holiday/Vacation not?
Crinetics Pharmaceuticals director Rogerio Vivaldi Coelho sold 5,000 shares of common stock on 12 March 2026, valued at approximately $181,000, according to an SEC Form 4 filing. The sale was executed under a Rule 10b5-1 trading plan adopted on 11 December 2025. The transaction reduced Coelho's direct holdings by 23.47%, from 21,300 to 16,300 shares, worth approximately $595,000. Shares were sold at a weighted average price of $36.15, close to the market price of $36.51 on the transaction date. This marks Coelho's only disclosed open-market sale for the clinical-stage biotechnology company, which develops oral therapeutics for rare endocrine diseases. Crinetics had a market capitalisation of $3.97 billion as of 12 March 2026.
Crinetics (NASDAQ: CRNX) coo-level executive Jeff Knight to resign by April 10, 2026. Filing Impact Filing Sentiment Rhea-AI Filing summary. Crinetics Pharmaceuticals announced that Jeff Knight has decided to resign as Chief Development and Operating Officer, effective on or about April 10, 2026. The company states that he is leaving to pursue another opportunity and that his resignation is not due to any disagreement over operations, policies, or practices. Crinetics plans to reassign all of Mr. Knight's managerial responsibilities and direct reports to other members of its executive leadership team, signaling a redistribution of his duties rather than the creation of a new replacement role at this time. Insights. Senior operating executive departs; duties redistributed internally. The departure of the Chief Development and Operating Officer at Crinetics Pharmaceuticals is notable because it affects leadership over development and operations. The company clarifies he is leaving to pursue another opportunity and explicitly notes no disagreements over corporate matters. All of his responsibilities will shift to other executive leaders, indicating an internal reallocation rather than an immediate external hire. The long-term impact will depend on how smoothly this transition proceeds and whether future disclosures outline any organizational or strategic changes following his exit effective on or about April 10, 2026. 03/23/2026 - 09:04 AM Faq. Why did Jeff Knight resign from Crinetics Pharmaceuticals (CRNX)? Jeff Knight resigned as Chief Development and Operating Officer to pursue another opportunity. The company states his resignation is not related to any disagreement regarding operations, policies, or practices, suggesting a voluntary career move rather than a dispute-driven departure. When will Jeff Knight's resignation from Crinetics Pharmaceuticals (CRNX) become effective? Jeff Knight's resignation as Chief Development and Operating Officer is effective on or about April 10, 2026. Until then, he remains in his role while the company prepares to reassign his responsibilities to other members of its executive leadership team. Did Jeff Knight have any disagreements with Crinetics Pharmaceuticals (CRNX) before resigning? Crinetics Pharmaceuticals states that Jeff Knight's resignation is not related to any disagreement with the company. This includes no disputes regarding operations, policies, or practices, indicating the departure is not tied to reported internal conflict or governance issues. How will Crinetics Pharmaceuticals (CRNX) handle Jeff Knight's responsibilities after his resignation? Crinetics plans to reassign all of Jeff Knight's managerial responsibilities and direct reports to other executive leadership team members. This approach redistributes his development and operating duties internally rather than immediately appointing a direct successor or creating a new standalone role. What executive role did Jeff Knight hold at Crinetics Pharmaceuticals (CRNX)? Jeff Knight served as Chief Development and Operating Officer at Crinetics Pharmaceuticals. This combined role covered leadership over drug development and operational functions, which the company now intends to redistribute among other executives following his effective resignation date in April 2026. Does the resignation announcement for CRNX mention any changes to company strategy? The announcement focuses on Jeff Knight's resignation and the reassignment of his responsibilities. It does not outline specific strategic changes, instead emphasizing that duties will move to other executive leaders and that the departure is not due to disagreements over company operations or policies. Filing exhibits & attachments. 3 documents
Crinetics Pharmaceuticals reported early commercial success for PALSONIFY (paltusotine), its acromegaly treatment, with $5.4 million in first-quarter revenue and over 200 patient starts. The drug, priced at $290,000 annually, has attracted 125-plus unique prescribers across academic and community settings. The company received a positive CHMP recommendation for paltusotine in Europe, with approval expected around May. CFO Tobin Schilke said Crinetics is well funded into 2030 following recent capital raising. The pipeline focuses on novel small-molecule GPCR therapies, including atumelnant advancing to Phase 3 for congenital adrenal hyperplasia and paltusotine entering Phase 3 for carcinoid syndrome. On reimbursement, over half of patients secured coverage through medical exceptions, whilst others receive temporary support through a Quick Start programme.
Crinetics Pharmaceuticals reported Q4 revenue of $6.2 million, including $5.4 million from PALSONIFY, its first commercial product launched in the US. The company has seen early adoption with over 125 unique prescribers and more than 200 enrollment forms, whilst several major payers have added the drug to formularies with label-aligned prior authorisation. The company announced atumelnant, the first ACTH receptor antagonist tested in humans, will enter a global phase II/III trial in the first half of 2025 for ACTH-dependent Cushing's syndrome. Crinetics used $326.2 million cash in 2025 and, following a January 2026 offering, has approximately $1.4 billion in cash and investments. Management provided 2026 GAAP operating expense guidance of $600–650 million, with funds expected to support operations into 2030.
Crinetics Pharmaceuticals has priced an underwritten public offering of 7.62 million shares of common stock at $45.95 per share, expecting to raise approximately $350 million in gross proceeds. The company has also granted underwriters a 30-day option to purchase up to an additional 1.14 million shares. The San Diego-based pharmaceutical company, which focuses on treatments for endocrine diseases and endocrine-related tumours, plans to use the net proceeds to fund commercial activities for its recently approved drug PALSONIFY™, research and development of product candidates, and general corporate purposes. The offering is expected to close on 8 January 2026. Leerink Partners, J.P. Morgan, Evercore ISI, Piper Sandler and Cantor are acting as joint bookrunning managers for the offering.